USPTO serial 79083827
SALUBRIS
Reviewed by CopyMark Law Group
Reg. 3972681Status 404
- Filing date
- Status date
- Registration date
- Jun 7, 2011
- Examiner
- POVARCHUK, REBECCA JOYCE
- Law office
- TMO LAW OFFICE 115
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SALUBRIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
SHENZHEN, CN
Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
SHENZHEN SALUBRIS PHARMACEUTICALS; CO.,LTD
SHENZHEN, CN
Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS; CO.,LTD
SHENZHEN SALUBRIS PHARMACEUTICALS; CO., LTD
CN
Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS; CO., LTD
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; chemico-pharmaceutical preparations, namely, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; chemical preparations for pharmaceutical purposes, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; medicines for human purposes, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; troches, namely, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; pharmaceutical products, namely, active pharmaceutical ingredients which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; prepared Chinese medicines, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; biochemical medicines, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; dietetic substances adapted for medical use, namely, beverages or food which are used for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; capsules for pharmaceutical purposes containing pharmaceutical preparations, specifically for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; drugs for medical purposes, namely, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
- Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS; CO.,LTD
- Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS; CO., LTD
- Other trademarks in Class 005
- Similar marks named SALUBRIS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 4, 2020 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Dec 4, 2020 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Sep 27, 2019 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jul 1, 2019 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Jul 1, 2019 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jun 12, 2019 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Oct 12, 2018 | C71T | CANCELLED SECTION 71 | — |
| Oct 10, 2018 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 3, 2018 | PR71 | POST REGISTRATION ACTION MAILED - SEC.71 | — |
| Dec 19, 2017 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 6, 2017 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Dec 6, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 25, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 1, 2011 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 1, 2011 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 7, 2011 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 7, 2011 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 22, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 3, 2011 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 3, 2011 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 2, 2011 | NPUB | NOTICE OF PUBLICATION | — |
| Feb 16, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 11, 2011 | ALIE | ASSIGNED TO LIE | — |
| Jan 20, 2011 | CRML | CORRESPONDENCE MAILED | — |
| Jan 19, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 19, 2011 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 19, 2011 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 19, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 19, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 19, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 18, 2010 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 25, 2010 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 25, 2010 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 25, 2010 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 24, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 23, 2010 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 19, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 15, 2010 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |